SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Hypertension Diagnostics, Inc. (HDII) .
本页证实的标准:
- VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。
SharesGrow 综合评分： 35/100 其中 0/7 项标准通过。
SharesGrow 7-Criteria Score
✗
健康
83/100
Debt-to-Equity & liquidity
→ Health
估值概览 — HDII
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.00
EV/EBITDA0.0
每股数据
EPS (TTM)$0.00
每股账面价值$0.00
每股营收$0.00
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2010 |
$-0.02 |
$1.38M |
$-990K |
-71.5% |
| 2011 |
$0.01 |
$1.39M |
$406.31K |
29.3% |
| 2012 |
$-0.02 |
$3.16M |
$-1.14M |
-36.1% |
| 2017 |
$-11.87 |
$3.57M |
$-622K |
-17.4% |
| 2018 |
$0.00 |
$3.68M |
$-369K |
-10% |
| 2019 |
$0.00 |
$3.79M |
$-125K |
-3.3% |
| 2020 |
$0.02 |
$0.00 |
$3.29M |
- |
| 2021 |
$0.00 |
$0.00 |
$-11K |
- |
| 2022 |
$0.00 |
$0.00 |
$-93.25K |
- |
| 2023 |
$0.00 |
$0.00 |
$0.00 |
- |
